Roy Marcus is a Nephrology physician. OpenAlex indexes 13 publications with 609 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
30 Medical Center Blvd
Suite 303
Upland, PA 190133955
Telephone
610-872-8501Registry record last updated 26 Jul 2012.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca UK LimitedProgram year20251 payment
- Amgen Inc.Program year20251 payment
- Novartis Pharmaceuticals CorporationProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
81.6%Statin21.2%Atorvastatin Calcium69%Simvastatin31%Part D<11 patientsalpha-Adrenergic Blocker14.1%Doxazosin Mesylate100%Part D≥12 patients+ 6 more classes in this area
Metabolism & gastrointestinal
9.1%SGLT2 inhibitor5.6%Farxiga100%Part D<11 patientsVitamin D3 Analog3.4%Calcitriol100%Part D<11 patientsOther
5.9%Phosphate Binder5.9%Sevelamer Carbonate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Sex Differences in SGLT2 Inhibitor Use Complicating a Treatment Optimization Program in a Large Network of Nephrology Practices
Journal of the American Society of Nephrology
2025 - Improving Quality of CKD Care with Individual Performance Reporting and Peer Mentoring: Results from GEMINI Phase 2
Journal of the American Society of Nephrology
2025 - Increasing Use of SGLT2 Inhibitors in Patients with CKD and Heart Failure through Physician Education and Outreach Reduces Inpatient Admissions in a Value-Based Care Model
Journal of the American Society of Nephrology
2024 - Encouraging a Standardized ESKD Transition Pathway in Value-Based Care (VBC) Patients Is Associated with a High Optimal Dialysis Start Rate
Journal of the American Society of Nephrology
2024 - A Standardized Care Pathway Increases Optimal Dialysis Starts
The American Journal of Managed Care
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Giuseppe Remuzzi
Mario Negri Institute for Pharmacological Research
Marcello Tonelli
University of Calgary
Johan Ärnlöv
Dalarna University
Juan Jesús Carrero
Danderyds sjukhus
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”